Roland Seiler

About

Roland Seiler is a leading urologic oncologist whose research centers on bladder cancer treatment, urinary diversion, and minimally invasive surgical techniques for benign prostatic obstruction. His most impactful work explores perioperative chemoimmunotherapy for muscle-invasive urothelial carcinoma (MIUC), notably as lead author of the SAKK 06/17 phase II trial (32 citations), which investigates combining durvalumab with cisplatin/gemcitabine before surgery—a strategy aimed at reducing high relapse rates in standard neoadjuvant therapy. Seiler also contributed to the ICUD–SIU International Consultation on Bladder Cancer 2018 update on urinary diversion (27 citations), shaping global consensus on post-cystectomy management. His comparative analysis of robot-assisted versus open cystectomy and a 2025 meta-synthesis of guidelines for benign prostatic obstruction treatments reflect his commitment to evidence-based surgical innovation. With over 60 publications, Seiler’s work bridges oncology and urology, advancing both curative-intent protocols and patient-centered surgical decision-making. His research is widely cited by clinicians and trialists seeking to optimize outcomes in urothelial carcinoma and lower urinary tract disorders.

Research Focus

Key Achievements

Top Papers

1. 1
   Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin/gemcitabine (Cis/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): Preplanned interim analysis of a single-arm phase II trial (SAKK 06/17).

   32 citations · 2020
2. 2
   Update of the ICUD–SIU International Consultation on Bladder Cancer 2018: urinary diversion

   27 citations · 2018
3. 3
   Robot-assisted versus open cystectomy

   4 citations · 2018
4. 4
   Surgical treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: an analysis and meta-synthesis of available guidelines

   3 citations · 2025

Key Collaborators

Contact & Links